These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 8892677

  • 1. Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
    Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, Löwenberg B.
    Leukemia; 1996 Nov; 10(11):1741-50. PubMed ID: 8892677
    [Abstract] [Full Text] [Related]

  • 2. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
    Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, Sonneveld P, Greipp PR.
    Cancer; 2006 Feb 15; 106(4):830-8. PubMed ID: 16419071
    [Abstract] [Full Text] [Related]

  • 3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Feb 15; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 4. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
    Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJ, Eeltink C, Vermorken JB, Pinedo HM.
    Clin Cancer Res; 1997 Nov 15; 3(11):2005-15. PubMed ID: 9815591
    [Abstract] [Full Text] [Related]

  • 5. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
    Sonneveld P, Schoester M, de Leeuw K.
    J Clin Oncol; 1994 Aug 15; 12(8):1584-91. PubMed ID: 7518859
    [Abstract] [Full Text] [Related]

  • 6. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM.
    Cancer; 2002 Nov 15; 95(10):2160-8. PubMed ID: 12412170
    [Abstract] [Full Text] [Related]

  • 7. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E, Bloem AC, Sinnige HA, Lokhorst HM.
    Haematologica; 2007 Dec 15; 92(12):e130-1. PubMed ID: 18055977
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
    Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B, European Organization for Research and Treatment of Cancer (EORTC), Leukaemia Cooperative Group (LCG), Dutch Haemato-Oncology Cooperative Study Group (HOVON).
    Br J Haematol; 2001 Dec 15; 115(4):895-902. PubMed ID: 11843823
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.
    Minami H, Ohtsu T, Fujii H, Igarashi T, Itoh K, Uchiyama-Kokubu N, Aizawa T, Watanabe T, Uda Y, Tanigawara Y, Sasaki Y.
    Jpn J Cancer Res; 2001 Feb 15; 92(2):220-30. PubMed ID: 11223552
    [Abstract] [Full Text] [Related]

  • 10. Dose-dependent brain penetration of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin, in rats.
    Lemaire M, Bruelisauer A, Guntz P, Sato H.
    Cancer Chemother Pharmacol; 1996 Feb 15; 38(5):481-6. PubMed ID: 8765444
    [Abstract] [Full Text] [Related]

  • 11. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA.
    Cancer; 2006 Feb 15; 106(4):848-58. PubMed ID: 16404741
    [Abstract] [Full Text] [Related]

  • 12. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z, Elbl L, Vorlicek J, Hájek R, Hájek D, Hejlová N, Králová E, Novotná H.
    Acta Med Austriaca; 1994 Feb 15; 21(4):111-5. PubMed ID: 7871966
    [Abstract] [Full Text] [Related]

  • 13. [SDZ PSC 833: a novel modulator of MDR].
    Covelli A.
    Tumori; 1997 Feb 15; 83(5 Suppl):S21-4. PubMed ID: 9446255
    [Abstract] [Full Text] [Related]

  • 14. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
    Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE.
    J Clin Oncol; 1989 Apr 15; 7(4):415-24. PubMed ID: 2564428
    [Abstract] [Full Text] [Related]

  • 15. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
    Browman GP, Belch A, Skillings J, Wilson K, Bergsagel D, Johnston D, Pater JL.
    Br J Haematol; 1992 Nov 15; 82(3):555-9. PubMed ID: 1486035
    [Abstract] [Full Text] [Related]

  • 16. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
    Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A, Greek Myeloma Study Group.
    Ann Oncol; 2004 Jan 15; 15(1):134-8. PubMed ID: 14679133
    [Abstract] [Full Text] [Related]

  • 17. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G, Clark RE, Morris TC, Robertson M, Lucie NP, Anderson S, Paul J, Franklin IM.
    Br J Haematol; 2004 Sep 15; 126(6):792-8. PubMed ID: 15352982
    [Abstract] [Full Text] [Related]

  • 18. VAD-cyclosporine therapy for VAD-resistant multiple myeloma.
    Weber D, Dimopoulos M, Sinicrope F, Alexanian R.
    Leuk Lymphoma; 1995 Sep 15; 19(1-2):159-63. PubMed ID: 8574163
    [Abstract] [Full Text] [Related]

  • 19. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
    Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HG, Nieuwenhuis HK, Dekker AW, Lokhorst HM.
    J Clin Oncol; 1994 Jan 15; 12(1):115-9. PubMed ID: 7903690
    [Abstract] [Full Text] [Related]

  • 20. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
    Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM.
    Br J Haematol; 1999 Apr 15; 105(1):127-30. PubMed ID: 10233375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.